Who
Thomas J. Lynch Jr.
Director
Company insider
Files Form 4 as: Director, Natera; Director, Foghorn Therapeutics; EVP & Chief Scientific Officer, Bristol-Myers Squibb; Director, Infinity Pharmaceuticals.
In numbers
- Trades disclosed
- 59
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $335K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 6 Oct 2009
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —1,905 | filing |
| 26 Jun 2026filed 30 Jun 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Code A | —1,905 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 17 Jun 2025filed 17 Jun 2025 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $120K25,000 at $4.79 | filing |
| 26 Jun 2024filed 28 Jun 2024 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $88K16,000 at $5.52 | filing |
| 21 Jun 2023filed 22 Jun 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 Oct 2022filed 31 Oct 2022 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $263K32,000 at $8.23 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,296 at $0.00 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,298 at $0.00 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —6,296 at $0.00 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $157K3,351 at $46.88 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —5,298 at $0.00 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —773 at $0.00 | filing |
| 3 Apr 2019filed 5 Apr 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $132K2,820 at $46.88 | filing |
| 10 Mar 2019filed 13 Mar 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,864 at $0.00 | filing |
| 10 Mar 2019filed 13 Mar 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —29,910 at $0.00 | filing |
| 10 Mar 2019filed 13 Mar 2019 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —44,865 at $0.00 | filing |
| 10 Mar 2019filed 13 Mar 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —5,864 at $0.00 | filing |
| 10 Mar 2019filed 13 Mar 2019 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —1,387 at $0.00 | filing |
News
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?BMY · fool.com · 21 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?BMY · fool.com · 20 Oct 2026Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should KnowBMY · aol.com · 16 Oct 2026
0 headlines in the last 90 days name Thomas J. Lynch Jr.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.